TrialCurveMIND-DC: reconstructed Kaplan–Meier curves
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Commun. 2024 Feb 23;15:1632. doi: 10.1038/s41467-024-45358-0 |
|---|---|
| DOI | 10.1038/s41467-024-45358-0 |
| Registry | NCT02993315 |
| Phase | Phase 3 |
| Conditions | Melanoma (Skin) |
| Interventions | nDC vaccination, placebo injection |
| Sponsor | Radboud University Medical Center |
| Enrolment | 148 |
| Source licence | Figure published under CC BY 4.0 |
Recurrence-free survival
From figure panel a · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: placebo 19.7 months; nDC 12.9 months. Survival at 18 months: placebo 51%; nDC 40%. Hazard ratio placebo vs nDC 0.81 (95% CI 0.53–1.23).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| placebo | 49 | 31 | 19.7 |
| nDC | 99 | 69 | 12.9 |
- placebo vs nDC: reconstructed HR 0.81 (95% CI 0.53–1.23)
Landmark survival (reconstructed)
| Time | placebo | nDC |
|---|---|---|
| 6 mo | 69.4% | 65.7% |
| 12 mo | 57.1% | 50.4% |
| 18 mo | 51.0% | 40.1% |
| 24 mo | 46.8% | 37.0% |
| 36 mo | 42.5% | 31.9% |
| 48 mo | 38.0% | 30.8% |
| 60 mo | 35.8% | 29.7% |
Overall survival
From figure panel b · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: placebo not reached; nDC not reached. Survival at 18 months: placebo 96%; nDC 93%. Hazard ratio placebo vs nDC 0.76 (95% CI 0.38–1.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| placebo | 49 | 11 | not reached |
| nDC | 99 | 27 | not reached |
- placebo vs nDC: reconstructed HR 0.76 (95% CI 0.38–1.54)
Landmark survival (reconstructed)
| Time | placebo | nDC |
|---|---|---|
| 6 mo | 100.0% | 99.0% |
| 12 mo | 98.0% | 95.9% |
| 18 mo | 95.9% | 92.9% |
| 24 mo | 91.8% | 84.7% |
| 36 mo | 85.7% | 76.5% |
| 48 mo | 79.3% | 72.0% |
| 60 mo | 76.8% | — |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- SCANDIUM: Hepatic progression-free survival (blinded central review); Progression-free survival (bli
- RELATIVITY-098: Distant metastasis-free survival (DMFS); Overall survival; Recurrence-free survival (RFS)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials